{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a97ae715",
   "metadata": {},
   "outputs": [],
   "source": [
    "!python -m spacy download en_core_web_lg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "2d539dff",
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "from spacy.tokens import DocBin\n",
    "from tqdm import tqdm\n",
    "import json\n",
    "import PyPDF2\n",
    "from PyPDF2 import PdfReader\n",
    "import re\n",
    "\n",
    "ce_nlp = spacy.blank(\"en\")  # a new spacy model\n",
    "db = DocBin() # a new DocBin object"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "f253ce90",
   "metadata": {},
   "outputs": [],
   "source": [
    "annotFile = open(r'C:\\Users\\abhijat_thakare\\Desktop\\Semicolons\\CriteriaExtractor\\Resources\\annotations.json')\n",
    "TRAIN_DATA = json.load(annotFile)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "9e8a4ec4",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 5/5 [00:00<00:00,  6.70it/s]\n"
     ]
    }
   ],
   "source": [
    "for text, annot in tqdm(TRAIN_DATA['annotations']): \n",
    "    doc = ce_nlp.make_doc(text) \n",
    "    ents = []\n",
    "    for start, end, label in annot[\"entities\"]:\n",
    "        span = doc.char_span(start, end, label=label)\n",
    "        if span is None:\n",
    "            print(\"Skipping entity\")\n",
    "        else:\n",
    "            ents.append(span)\n",
    "    doc.ents = ents \n",
    "    db.add(doc)\n",
    "\n",
    "db.to_disk(\"./training_data.spacy\") # save the docbin object"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "5dffb0b1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;3m[!] To generate a more effective transformer-based config (GPU-only),\n",
      "install the spacy-transformers package and re-run this command. The config\n",
      "generated now does not use transformers.\u001b[0m\n",
      "\u001b[38;5;4m[i] Generated config template specific for your use case\u001b[0m\n",
      "- Language: en\n",
      "- Pipeline: ner\n",
      "- Optimize for: efficiency\n",
      "- Hardware: CPU\n",
      "- Transformer: None\n",
      "\u001b[38;5;2m[+] Auto-filled config with all values\u001b[0m\n",
      "\u001b[38;5;2m[+] Saved config\u001b[0m\n",
      "config.cfg\n",
      "You can now add your data and train your pipeline:\n",
      "python -m spacy train config.cfg --paths.train ./train.spacy --paths.dev ./dev.spacy\n"
     ]
    }
   ],
   "source": [
    "! python -m spacy init config config.cfg --lang en --pipeline ner --optimize efficiency"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "b387c71f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;4m[i] Saving to output directory: .\u001b[0m\n",
      "\u001b[38;5;4m[i] Using CPU\u001b[0m\n",
      "\u001b[1m\n",
      "=========================== Initializing pipeline ===========================\u001b[0m\n",
      "\u001b[38;5;2m[+] Initialized pipeline\u001b[0m\n",
      "\u001b[1m\n",
      "============================= Training pipeline =============================\u001b[0m\n",
      "\u001b[38;5;4m[i] Pipeline: ['tok2vec', 'ner']\u001b[0m\n",
      "\u001b[38;5;4m[i] Initial learn rate: 0.001\u001b[0m\n",
      "E    #       LOSS TOK2VEC  LOSS NER  ENTS_F  ENTS_P  ENTS_R  SCORE \n",
      "---  ------  ------------  --------  ------  ------  ------  ------\n",
      "  0       0          0.00   1880.60    0.00    0.00    0.00    0.00\n",
      " 20     200      24429.61  87397.64  100.00  100.00  100.00    1.00\n",
      " 40     400          0.00      0.00  100.00  100.00  100.00    1.00\n",
      " 60     600          0.00      0.00  100.00  100.00  100.00    1.00\n",
      " 80     800          0.00      0.00  100.00  100.00  100.00    1.00\n",
      "100    1000          0.00      0.00  100.00  100.00  100.00    1.00\n",
      "120    1200          0.00      0.00  100.00  100.00  100.00    1.00\n",
      "140    1400          0.00      0.00  100.00  100.00  100.00    1.00\n",
      "160    1600          0.00      0.00  100.00  100.00  100.00    1.00\n",
      "180    1800          0.00      0.00  100.00  100.00  100.00    1.00\n",
      "\u001b[38;5;2m[+] Saved pipeline to output directory\u001b[0m\n",
      "model-last\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[2023-02-23 23:32:33,984] [INFO] Set up nlp object from config\n",
      "[2023-02-23 23:32:33,993] [INFO] Pipeline: ['tok2vec', 'ner']\n",
      "[2023-02-23 23:32:33,996] [INFO] Created vocabulary\n",
      "[2023-02-23 23:32:33,997] [INFO] Finished initializing nlp object\n",
      "[2023-02-23 23:32:51,605] [INFO] Initialized pipeline components: ['tok2vec', 'ner']\n"
     ]
    }
   ],
   "source": [
    "! python -m spacy train config.cfg --output ./ --paths.train ./training_data.spacy --paths.dev ./training_data.spacy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "462ef4e1",
   "metadata": {},
   "outputs": [],
   "source": [
    "ce_nlp_ner = spacy.load(\"./model-best\") "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "778b1393",
   "metadata": {},
   "outputs": [],
   "source": [
    "def all_work(nlp_text):\n",
    "    doc = ce_nlp_ner(nlp_text)\n",
    "    spacy.displacy.render(doc, style=\"ent\", jupyter=True) # display in Jupyter\n",
    "    lis = []\n",
    "    for entity in doc.ents:\n",
    "        lis.append({entity.label_ : entity})\n",
    "    return lis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "686c0b72",
   "metadata": {},
   "outputs": [],
   "source": [
    "def GenerateTextOutput(pdf_path):\n",
    "    \n",
    "    ExtractedPDFText = \"\"\n",
    "    reader = PdfReader(pdf_path)\n",
    "    number_of_pages = len(reader.pages)\n",
    "    for i in range(number_of_pages) :\n",
    "        page = reader.pages[i]\n",
    "        ExtractedPDFText += page.extract_text()\n",
    "        \n",
    "    New_text = re.sub(r'https?://\\S+|www\\.\\S+', '', ExtractedPDFText) #Remove links\n",
    "    New_text = re.sub(r'\\w+:\\/{2}[\\d\\w-]+(\\.[\\d\\w-]+)*(?:(?:\\/[^\\s/]*))*', '', New_text) #Remove links\n",
    "    New_text = re.sub(r'\\S+\\.gov\\S*\\b', '', New_text) #Remove links\n",
    "    New_text = re.sub(r'Page\\s+\\d+\\s+of\\s+\\d+', '', New_text) #Remove page numbers\n",
    "\n",
    "\n",
    "    #Replace Symbols\n",
    "\n",
    "    New_text = New_text.replace(\"<\", \" < \")\n",
    "    New_text = New_text.replace(\">\", \" > \")\n",
    "    New_text = New_text.replace(\"≥\", \" >= \")\n",
    "    New_text = New_text.replace(\"≤\", \" <= \")\n",
    "    New_text = New_text.replace(\"…\", \" ... \")\n",
    "    New_text = New_text.replace(\"•\", \" \")\n",
    "    New_text = New_text.replace(\"—\", \" \")\n",
    "    New_text = New_text.replace(\"’\", \" \")\n",
    "    New_text = New_text.replace(\"°\", \" \")\n",
    "    New_text = New_text.replace(\"∀\", \" \")\n",
    "    New_text = New_text.replace(\"∃\", \" \")\n",
    "    New_text = New_text.replace(\"é\", \"e\")\n",
    "    New_text = New_text.replace(\"”\", \" \")\n",
    "    New_text = New_text.replace(\"ä\", \" \")\n",
    "    New_text = New_text.replace(\":\", \" : \")\n",
    "    New_text = New_text.replace(\",\", \" , \")\n",
    "    New_text = New_text.replace(\"^\", \" \")\n",
    "    New_text = New_text.replace(\"ï\", \"i\")\n",
    "    New_text = New_text.replace(\"–\", \" - \")\n",
    "    New_text = New_text.replace(\"ö\", \"o\")\n",
    "    New_text = New_text.replace(\"“\", \" \")\n",
    "    \n",
    "    return New_text\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "a627eeef",
   "metadata": {},
   "outputs": [],
   "source": [
    "res = GenerateTextOutput(r'C:\\Users\\abhijat_thakare\\Desktop\\Converted_NCT04716946.pdf')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "3fdacaba",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  </br>    We're building a better  . Check it out and tell us what you think!  </br> </br> </br>Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and </br>Radiation Therapy  </br> </br>The safety and scientific validity of this study is the responsibility of the study </br>sponsor and investigators. Listing a study does not mean it has been  evaluated </br>by the U.S. Federal Government. Know the risks and potential benefits  of clinical </br>studies and talk to your health care provider before participating. Read our </br>disclaimer  for details.  </br>  </br> Identifier :  NCT04716946  </br>Recruitment Status !  :  Recruiting  </br>First Posted !  :  January 20 ,  2021  </br>Last Update Posted !  :  January 20 ,  2023  </br>See Contacts and Locations  </br>View this study on   </br>Sponsor :   </br>Memorial Sloan Kettering Cancer Center  </br>Collaborator :   </br>AstraZeneca  </br>Information provided by (Responsible Party) :   </br>Find Studie  </br>s </br>About Studie  </br>s </br>Submit Studie  </br>s </br>Resource  </br>s </br>About Sit  </br>e </br>PRS Logi  </br>n Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  </br>   Memorial Sloan Kettering Cancer Center  </br> </br>Brief Summary :   </br>The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a </br>type of radiation therapy called stereotactic body radiation (SBRT) is a more e ffective treatment for early -</br>stage non -small cell lung cancer (NSCLC) t han SBRT alone.  </br>Condition or disease ! Intervention/treatment ! Phase  </br>! </br>NSCLC  </br>Non-small Cell Lung Cancer  </br>Lung Cancer  </br>Non-small Cell Lung Cancer </br>Stage I  </br>Non-small Cell Lung Cancer </br>Stage II  </br>Non-small Cell Lung Cancer </br>Stage III  </br>Non-small Cell Lung Cancer </br>Stage IIIA  </br>PD-L1 Gene Mutation  Drug :  Durvalumab  </br>Radiation :  Stereotactic Body  </br>Radiation Therapy  Phase 2  </br> </br>Study Type !  :  Interventional  (Clinical </br>Trial)  </br>Estimated Enrollment !  :  40 participants  </br>Allocation :   N/A </br>Intervention Model :   Single Group Assignment  </br>Masking :   None (Open Label)  </br> </br>Primary Purpose :   Treatment  </br>Study Details  </br> Tabular Vie  </br>w </br> No Results Poste  </br>d </br> Disclaime  </br>r </br>How to Read a Study Recor  </br>d </br>Study Description  </br> Go </br>  </br>to </br>  </br>  </br>Study Design  </br> Go </br>  </br>to </br>  </br>  </br>Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  </br>   Official Title :   Stereotactic Body Radiation Therapy With Consolidation  </br>Durvalumab in High -Risk Early -Stage Non -Small Cell Lung  </br>Cancer - A Phase II Single -Arm Trial  </br>Actual Study Start Date !  :  January 27 ,  2021  </br>Estimated Primary Completion Date !  :  February 2024  </br>Estimated Study Completion Date !  :  February 2024  </br> </br>Arm ! Intervention/treatment ! </br>Experimental :  Participants with Early -stage Non - </br>Small Cell Lung Cancer  </br>Participants will be diagnosed with Stage </br>IIIIA NSCLC and will be ineligible for </br>surgery and will have any level of PD -L1 Drug :  Durvalumab  </br>Patients will receive durvalumab 1500mg </br>durva lumab via IV infusion over 1 hour ,  </br>once every 4 weeks (Q4W) for up to a </br>maximum of 6 months (up to 6  </br>doses/cycles) unless there is unacceptable </br>toxicity ,  withdrawal of consent ,  or another </br>discontinuation criterion is met.  </br>Radiation :  Stereotactic Body Radiation Therapy  </br>Radiation therapy will be performed with </br>external beam ionizing radiation in </br>accordance with institutional standard </br>practice. 3D conformal radiation therapy </br>(3D-CRT) ,  intensity -modulated radiation  </br>Resource links provided by the National Library of Medicine  </br>MedlinePlus Genetic  </br>s </br> related topics :   </br> g </br> Lun </br>  </br>cance  </br>r </br>MedlinePlu  </br>s </br> related topics :   </br>Lun </br>g </br>  </br>Cance  </br>r </br>Drug Informatio  </br>n </br> available for :   </br>Durvaluma  </br>b </br>U.S. FDA Resource  </br>s </br>Arms and Interventions  </br> Go </br>  </br>to </br>  </br>  </br>Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  </br>   </br> therapy (IMRT) or volumetric arc therapy </br>(VMAT) will be used at the discretion of the </br>treating radiation oncologist.  </br>Other Name :  SBRT  </br> </br>Primary Outcome Measures !  :  </br>1. Progression Free Survival [  Time  Frame :   2 years  ] </br>The primary objective of the study is to evaluate 2 - year progression -free survival (PFS) per </br>RECIST 1.1 with durvalumab combined with stereotactic body radiation therapy (SBRT) </br>compared to historical controls with SBRT alone.  </br> </br>Information from the National Library of Medicine  </br>Choosing to participate in a study is an important personal decision. Talk </br>with your doctor and family members or friends about deciding to join a </br>study. To learn more about this study ,  you or your doctor may contact the </br>study research staff using the cont acts provided below. For general </br>information ,  Learn About Clinical Studies.  </br>Ages Eligible for Study :    18 Years and older   (Adult ,  Older Adult) </br>Sexes Eligible for Study :    All </br> Accepts Healthy Volunteers :    No </br>Criteria  </br>\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Inclusion Criteria :   \n",
       " Capable of giving signed informed consent which includes compliance with the requirements  \n",
       "Outcome Measures  \n",
       " Go \n",
       "  \n",
       "to \n",
       "  \n",
       "  \n",
       "Eligibility Criteria  \n",
       " Go \n",
       "  \n",
       "to \n",
       "  \n",
       "  \n",
       "Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "   and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed \n",
       "consent and any locally required authorization obtained from the patient/legal representative \n",
       "prior to performing any protocol - related procedures.  \n",
       "Patient a ge  &gt;=  18 at time of consent  \n",
       "Early stage NSCLC (Stage I to IIIA; T1 -4 excluding patients with satellite nodules in the same \n",
       "or ipsilateral lobes ,  N0; AJCC 8th edition)  \n",
       " Ineligible for or unwilling to undergo surgical resection. Reasons for surgical ineligib ility \n",
       "include :  medically inoperable or surgically unresectable (due to tumor size ,  location etc.) ,  as \n",
       "assessed by MSKCC thoracic surgeon or multi -disciplinary tumor board consensus. Reasons \n",
       "for ineligibility or patient's unwillingness to undergo surgical r esection must be clearly \n",
       "documented.  \n",
       " Histological and/or cytological confirmation of NSCLC as per standard of care biopsy; no \n",
       "additional research protocol -specific biopsy is needed.  \n",
       "ECOG/WHO PS 0 -1 (KPS 70 -100) \n",
       "Candidates for definitive SBRT  \n",
       "  If ,  after  candidates have been planned for RT ,  they are unable to be treated with the \n",
       "institutional dose constraints as listed in the appendix ,  they will be labeled ineligible and \n",
       "removed from the study. Ineligible patients will be replaced.  \n",
       " A predicted 2 -year PF S of  &lt; 80% (  &gt;= 20% risk for disease progression) based on an \n",
       "MSKCCdeveloped radiomics risk prediction model (see section 9.0).  \n",
       "Body weight  &gt;  30kg  \n",
       "Adequate normal organ and marrow function as defined below :   \n",
       "Hemoglobin  &gt;= 9.0 g/dL  \n",
       "Absolute neutrophil count (ANC)  1.5 x ( &gt;  1500 per mm 3)  \n",
       "Platelet count  &gt;= 75 x 10 9/L ( &gt; 75 , 000 per mm 3)  \n",
       "Serum bilirubin  &lt;= 1.5 x institutional upper limit of normal (ULN). This will not apply to \n",
       "patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is \n",
       "predominantly unconjugated in the absence of hemolysis or hepatic pathology) ,  who will be \n",
       "allowed only in consultation with their physician.  \n",
       "AST (SGOT)/ALT (SGPT)  &lt;= 2.5 x institutional upper limit of normal  \n",
       "Evidence of post -menopausal status or negative urinary or serum pregnancy test for female \n",
       "pre-menopausal patients. Women will be considered postmenopausal if they have been \n",
       "amenorrheic for 12 months without an alternative medical cause. The following age - specific \n",
       "requirements apply :   Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "    Women  &lt; 50 years of age would be considered post -menopausal if they have been \n",
       "amenorrheic for 12 months or more following cessation of exogenous hormonal \n",
       "treatments and if they have luteinizing hormone and follicle -stimulating  hormone levels in \n",
       "the postmenopausal range for the institution or underwent surgical sterilization (bilateral \n",
       "oophorectomy or hysterectomy).  \n",
       " Women  &gt;= 50 years of age would be considered post -menopausal if they have been \n",
       "amenorrheic for 12 months or more f ollowing cessation of all exogenous hormonal treatments ,  \n",
       "had radiation -induced menopause with last menses  &gt; 1 year ago ,  had chemotherapy -induced \n",
       "menopause with last menses  &gt; 1 year ago ,  or underwent surgical sterilization (bilateral \n",
       "oophorectomy ,  bilateral s alpingectomy or hysterectomy).  Must have a life expectancy of at \n",
       "least 12 weeks\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">INCLUSIONCRITERIA</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Exclusion Criteria :   \n",
       "Participation in another clinical study with an investigational product during the last 4 weeks.  \n",
       "Previous thoracic radiation precluding definitive SBRT t o the current tumor.  \n",
       "Active or prior documented autoimmune or inflammatory disorders (including inflammatory \n",
       "bowel disease [e.g. ,  colitis or Crohn's disease] ,  diverticulitis [with the exception of diverticulosis] ,  \n",
       "systemic lupus erythematosus ,  Sarcoidosis syndrome ,  or Wegener syndrome [granulomatosis \n",
       "with polyangiitis ,  Graves' disease ,  rheumatoid arthritis ,  hypophysitis ,  uveitis ,  etc]). The following \n",
       "are exceptions to this criterion :   \n",
       "1. Patients with vitiligo or alopecia  \n",
       "2. Patients with hypothyroidism (e.g. ,  fol lowing Hashimoto syndrome) stable on hormone \n",
       "replacement  \n",
       "3. Any chronic skin condition that does not require systemic therapy  \n",
       "4. Patients without active disease in the last 5 years may be included but only after \n",
       "consultation with the PI  \n",
       "5. Patients with celiac disease controlled by diet alone  \n",
       " Any unresolved toxicity NCI CTCAE Grade  &gt;= 2 from previous anticancer therapy with the \n",
       "exception of alopecia ,  vitiligo ,  and the laboratory values defined in the inclusion criteria  \n",
       "1. Patients with Grade  &gt;= 2 neuropathy will be evaluated on a case -by-case basis after \n",
       "consultation with the PI.  \n",
       "2. Patients wi th irreversible toxicity not reasonably expected to be exacerbated by \n",
       "treatment with durvalumab may be included only after consultation with the PI.  \n",
       " Prior/Current Therapies :   Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "   1. Treatment with a monoclonal antibody within 4 weeks prior to study Day 1 or has not \n",
       "recovered (i.e. ,   &gt;=  Grade 1 at baseline) from adverse events due to agents administered \n",
       " &gt;  4 weeks earlier (intraocular bevacizumab is acceptable).  \n",
       "2. Prior chemotherapy or targeted small molecule therapy ,  within 3 weeks prior to study \n",
       "Day 1 or has not reco vered (i.e. ,   &gt;=  Grade 1 at baseline) from adverse events due to a \n",
       "previously administered agent).  \n",
       "3. Prior therapy with an anti -PD-1 ,  anti -PD-L1 ,  including durvalumab ,  anti -PDL2 ,  \n",
       "antiCD137 ,  anti -Cytotoxic T - lymphocyte -associated antigen -4 (CTLA -4) antibody ,  o r \n",
       "any other antibody or drug specifically targeting T -cell co -stimulation or checkpoint \n",
       "pathways.  \n",
       "4. Current or prior use of immunosuppressive medication within 14 days before the first \n",
       "dose of durvalumab. The following are exceptions to this criterion :   \n",
       "i. Intranasal ,  inhaled ,  topical steroids ,  or local steroid injections (e.g. ,  intra articular injection) \n",
       "ii. Systemic corticosteroids at physiologic doses not to exceed  &lt;  &lt; 10 mg/day &gt;  &gt;  of prednisone \n",
       "or its equivalent iii. Steroids as premedication for hypersensiti vity reactions (e.g. ,  CT scan \n",
       "premedication) e. Any concurrent chemotherapy ,  IP ,  biologic ,  or hormonal therapy for cancer \n",
       "treatment. Concurrent use of hormonal therapy for non -cancer -related conditions (e.g. ,  \n",
       "hormone replacement therapy) is acceptable. f. Prior chemotherapy for this diagnosis of lung \n",
       "cancer  \n",
       " Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose \n",
       "of IP. Note :  Local surgery of isolated lesions for palliative intent is acceptable.  \n",
       "History of allogenic organ transplantation.  \n",
       "Severe concurrent illness :   \n",
       "1. Known psychiatric or substance abuse disorders that would interfere with cooperation \n",
       "with the requirements of the trial.  \n",
       "2. Known additional malignancy that is progressing or requires active treatment. \n",
       "Exceptions include basal cell carcinoma of the skin ,  squamo us cell carcinoma of the \n",
       "skin ,  or in situ cervical cancer that has undergone potentially curative therapy.  \n",
       "3. Active infection including tuberculosis (clinical evaluation that includes clinical history ,  \n",
       "physical examination and radiographic findings ,  and TB t esting in line with local \n",
       "practice) ,  hepatitis B (known positive HBV surface antigen (HBsAg) result) ,  hepatitis C ,  \n",
       "or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or \n",
       "resolved HBV infection (defined as the presence of hep atitis B core antibody [anti -HBc] \n",
       "and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are \n",
       "eligible only if polymerase chain reaction is negative for HCV RNA.  Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "   \n",
       "4. Active infection requiring systemic therapy.  \n",
       "5. Evidence of intersti tial lung disease or active ,  non -infectious pneumonitis.  \n",
       "6. Clinically significant (i.e. ,  active) cardiovascular disease :  symptomatic cerebral vascular \n",
       "accident/stroke ( &lt;  6 months prior to enrollment) ,  myocardial infarction ( &lt;  6 months prior \n",
       "to enrollment) ,  u nstable angina ,  congestive heart failure (  &gt;=  New York Heart  \n",
       "Association Classification Class II) ,  or serious cardiac arrhythmia requiring medication.  \n",
       " Female patients who are pregnant or breastfeeding or male or female patients of reproductive \n",
       "potential wh o are not willing to employ a highly e ffective birth control from screening to 90 \n",
       "days after the last dose of durvalumab monotherapy.  \n",
       "a. Highly e ffective methods of contraception ,  defined as one that results in a low failure rate \n",
       "(ie ,  less than 1% per year) when used consistently and correctly are described in Appendix B. \n",
       "Note that some contraception methods are not considered highly e ffective (e.g. male or \n",
       "female condom with or without spermicide; female cap ,  diaphragm ,  or sponge with or without \n",
       "spermicide; non -copper containing intrauterine device; progestogen -only oral hormonal \n",
       "contraceptive pills where inhibition of ovulation is not the primary mo de of action [excluding \n",
       "Cerazette/desogestrel which is considered highly e ffective]; and triphasic combined oral \n",
       "contraceptive pills).  \n",
       " Live vaccination within 4 weeks prior to the first dose of durvalumab and while on trial is \n",
       "prohibited except for admin istration of inactivated vaccines.  \n",
       " Connective tissue disorders or idiopathic pulmonary fibrosis involving the lungs and/or \n",
       "esophagus  \n",
       "Known actionable EGFR or ALK mutation \n",
       "Known contraindications to radiotherapy  \n",
       "History of leptomeningeal carcinomatosis  \n",
       "History of active primary immunodeficiency  \n",
       "Known allergy or hypersensitivity to any of the study drugs or any of the study drug \n",
       "excipients.  \n",
       " Prior randomization or treatment in a previous durvalumab clinical study regardless of \n",
       "treatment arm assignment.  \n",
       " Participants must not donate blood while on durvalumab therapy.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">EXCLUSIONCRITERIA</span>\n",
       "</mark>\n",
       "  </br>Contacts and Locations  Go to   </br> </br>Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  </br>   </br>Information from the National Library of Medicine  </br>To learn more about this study ,  you or your doctor may contact the study </br>research staff using the contact information provided by the sponsor.  </br>Please refer to this study by its  identifier (NCT number) :   </br>NCT04716946  </br>Contacts  </br> Contact :  Andr eas Rimner ,  MD  646-608-2449  Rimnera@MSKCC.ORG  </br> Contact :  Maria Thor ,  PhD ,  MS  646-888-8013  thorm@mskcc.org  </br>Locations  </br>United States ,  Connecticut  </br> Hartford Healthcare (Data Collection)  Recruiting  </br>Hartford ,  Connecticut ,  United States ,  06102  </br>Contact :  Helaine Ber tsch ,  MD    860-545-2803       </br>United States ,  Florida  </br> Baptist Alliance - McI Recruiting  </br>Miami ,  Florida ,  United States ,  33143  </br>Contact :  Rupesh Kotecha ,  MD    786-596-2000       </br>United States ,  New Jersey  </br> Memorial Sloan Kettering Basking Ridge  Recruiting  </br>Basking Ridge ,  New Jersey ,  United States ,  07920  </br>Contact :  Andreas Rimner ,  MD    646-608-2449       </br> Memorial Sloan Kettering Monmouth  Recruiting  </br>Middletown ,  New Jersey ,  United States ,  07748  </br>Contact :  Andreas Rimner ,  MD    646-608-2449       </br> Memorial Sloan Kettering Bergen  Recruiting  </br>Montvale ,  New Jersey ,  United States ,  07645  </br>Contact :  Andreas Rimner ,  MD    646-608-2449       </br>United States ,  New York  Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  </br>    Memorial Sloan Kettering Cancer Center @ Su ffolk - Commack  Recruiting  </br>Commack ,  New York ,  United States ,  11725  </br>Contact :  Andreas Rimner ,  MD    646-608-2449       </br> Memorial Sloan Kettering Westchester  Recruiting  </br>Harrison ,  New York ,  United States ,  10604  </br>Contac t :  Andreas Rimner ,  MD    646-608-2449       </br> Memorial Sloan Kettering Cancer Center  Recruiting  </br>New York ,  New York ,  United States ,  10065  </br>Contact :  Andreas Rimner ,  MD    646-608-2449       </br> Memorial Sloan Kettering Nassau  Recruiting  </br>Rockville Centre ,  New York ,  United States ,  11553  </br>Contact :  Andreas Rimner ,  MD    646-608-2449       </br>Sponsors and Collaborators  </br>Memorial Sloan Kettering Cancer Center </br>AstraZeneca  </br>Investigators  </br> Principal Investigator :   Andreas Rimner ,  MD  Memorial Sloan Kettering Cancer Center  </br> </br>Additional Information :   </br>Memorial Sloan Kettering Cancer Center    </br> Responsible Party :   Memorial Sloan Kettering Cancer Center  </br>  I dentifier :   NCT04716946      History of Changes  </br> Other Study ID Numbers :   20-415  </br> First Posted :   January 20 ,  2021    Key Record Dates  </br>Last Update Posted :   January 20 ,  2023 Last </br>Verified :   January 2023  </br>Individual Participant Data (IPD) Sharing Statement :   </br> Plan to Share IPD :   Yes </br>More Information  </br> Go </br>  </br>to </br>  </br>  </br>Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  </br>   Plan Description :   Memorial Sloan Kettering Cancer Center  supports the international </br>committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of </br>data from clinical trials. The protocol summary ,  a statistical summary ,  and informed consent form </br>will be made available on clinic  when required as a condition of Federal awards ,  other </br>agreements supporting the research and/or as otherwise required. Requests for deidentified </br>individual participant data can be made beginning 12 months after publication and for up to 36 </br>months post publication. Deidentified individual participant data reported in the manuscript will be </br>shared under the terms of a Data Use Agreement and may only be used for approved proposals. </br>Requests may be made to :  crdatashare@mskcc.org.  </br> Studies a U.S. FDA -regulated Drug Product :   Yes </br> Studies a U.S. FDA -regulated Device Product :   No </br>Keywords provided by Memorial Sloan Kettering Cancer Center :   </br>Durvalumab  </br>NSCLC  </br>Non-small Cell Lung Cancer  </br>Non-small Cell Lung Cancer Stage I  </br>Non-small Cell Lung Cancer Stage II  </br>Non-small Cell Lung Cancer Stage III  </br>Additional relevant MeSH terms :   Non-small Cell Lung Cancer Stage IIIA  </br>Lung Cancer  </br>PD-L1 Gene Mutation  </br>Early stage NSCLC  </br>20-145 </br>Memorial Sloan Kettering Cancer Center  </br>Lung Neoplasms  </br>Carcinoma ,  Non -Small -Cell Lung  </br>Respiratory Tract Neoplasms  </br>Thoracic Neoplasms  </br>Neoplasms by Site  </br>Neoplasms  Respiratory Tract Diseases  </br>Carcinoma ,  Bronchogenic  </br>Bronchial Neoplasms  </br>Durvalumab  </br>Antineoplastic Agents ,  Immunological  </br>Antineoplastic Agents  </br>Lung Diseases  </div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "newLis = all_work(res)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "35e05aa9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'INCLUSIONCRITERIA': Inclusion Criteria :   \n",
       "   Capable of giving signed informed consent which includes compliance with the requirements  \n",
       "  Outcome Measures  \n",
       "   Go \n",
       "    \n",
       "  to \n",
       "    \n",
       "    \n",
       "  Eligibility Criteria  \n",
       "   Go \n",
       "    \n",
       "  to \n",
       "    \n",
       "    \n",
       "  Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "     and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed \n",
       "  consent and any locally required authorization obtained from the patient/legal representative \n",
       "  prior to performing any protocol - related procedures.  \n",
       "  Patient a ge  >=  18 at time of consent  \n",
       "  Early stage NSCLC (Stage I to IIIA; T1 -4 excluding patients with satellite nodules in the same \n",
       "  or ipsilateral lobes ,  N0; AJCC 8th edition)  \n",
       "   Ineligible for or unwilling to undergo surgical resection. Reasons for surgical ineligib ility \n",
       "  include :  medically inoperable or surgically unresectable (due to tumor size ,  location etc.) ,  as \n",
       "  assessed by MSKCC thoracic surgeon or multi -disciplinary tumor board consensus. Reasons \n",
       "  for ineligibility or patient's unwillingness to undergo surgical r esection must be clearly \n",
       "  documented.  \n",
       "   Histological and/or cytological confirmation of NSCLC as per standard of care biopsy; no \n",
       "  additional research protocol -specific biopsy is needed.  \n",
       "  ECOG/WHO PS 0 -1 (KPS 70 -100) \n",
       "  Candidates for definitive SBRT  \n",
       "    If ,  after  candidates have been planned for RT ,  they are unable to be treated with the \n",
       "  institutional dose constraints as listed in the appendix ,  they will be labeled ineligible and \n",
       "  removed from the study. Ineligible patients will be replaced.  \n",
       "   A predicted 2 -year PF S of  < 80% (  >= 20% risk for disease progression) based on an \n",
       "  MSKCCdeveloped radiomics risk prediction model (see section 9.0).  \n",
       "  Body weight  >  30kg  \n",
       "  Adequate normal organ and marrow function as defined below :   \n",
       "  Hemoglobin  >= 9.0 g/dL  \n",
       "  Absolute neutrophil count (ANC)  1.5 x ( >  1500 per mm 3)  \n",
       "  Platelet count  >= 75 x 10 9/L ( > 75 , 000 per mm 3)  \n",
       "  Serum bilirubin  <= 1.5 x institutional upper limit of normal (ULN). This will not apply to \n",
       "  patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is \n",
       "  predominantly unconjugated in the absence of hemolysis or hepatic pathology) ,  who will be \n",
       "  allowed only in consultation with their physician.  \n",
       "  AST (SGOT)/ALT (SGPT)  <= 2.5 x institutional upper limit of normal  \n",
       "  Evidence of post -menopausal status or negative urinary or serum pregnancy test for female \n",
       "  pre-menopausal patients. Women will be considered postmenopausal if they have been \n",
       "  amenorrheic for 12 months without an alternative medical cause. The following age - specific \n",
       "  requirements apply :   Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "      Women  < 50 years of age would be considered post -menopausal if they have been \n",
       "  amenorrheic for 12 months or more following cessation of exogenous hormonal \n",
       "  treatments and if they have luteinizing hormone and follicle -stimulating  hormone levels in \n",
       "  the postmenopausal range for the institution or underwent surgical sterilization (bilateral \n",
       "  oophorectomy or hysterectomy).  \n",
       "   Women  >= 50 years of age would be considered post -menopausal if they have been \n",
       "  amenorrheic for 12 months or more f ollowing cessation of all exogenous hormonal treatments ,  \n",
       "  had radiation -induced menopause with last menses  > 1 year ago ,  had chemotherapy -induced \n",
       "  menopause with last menses  > 1 year ago ,  or underwent surgical sterilization (bilateral \n",
       "  oophorectomy ,  bilateral s alpingectomy or hysterectomy).  Must have a life expectancy of at \n",
       "  least 12 weeks},\n",
       " {'EXCLUSIONCRITERIA': Exclusion Criteria :   \n",
       "  Participation in another clinical study with an investigational product during the last 4 weeks.  \n",
       "  Previous thoracic radiation precluding definitive SBRT t o the current tumor.  \n",
       "  Active or prior documented autoimmune or inflammatory disorders (including inflammatory \n",
       "  bowel disease [e.g. ,  colitis or Crohn's disease] ,  diverticulitis [with the exception of diverticulosis] ,  \n",
       "  systemic lupus erythematosus ,  Sarcoidosis syndrome ,  or Wegener syndrome [granulomatosis \n",
       "  with polyangiitis ,  Graves' disease ,  rheumatoid arthritis ,  hypophysitis ,  uveitis ,  etc]). The following \n",
       "  are exceptions to this criterion :   \n",
       "  1. Patients with vitiligo or alopecia  \n",
       "  2. Patients with hypothyroidism (e.g. ,  fol lowing Hashimoto syndrome) stable on hormone \n",
       "  replacement  \n",
       "  3. Any chronic skin condition that does not require systemic therapy  \n",
       "  4. Patients without active disease in the last 5 years may be included but only after \n",
       "  consultation with the PI  \n",
       "  5. Patients with celiac disease controlled by diet alone  \n",
       "   Any unresolved toxicity NCI CTCAE Grade  >= 2 from previous anticancer therapy with the \n",
       "  exception of alopecia ,  vitiligo ,  and the laboratory values defined in the inclusion criteria  \n",
       "  1. Patients with Grade  >= 2 neuropathy will be evaluated on a case -by-case basis after \n",
       "  consultation with the PI.  \n",
       "  2. Patients wi th irreversible toxicity not reasonably expected to be exacerbated by \n",
       "  treatment with durvalumab may be included only after consultation with the PI.  \n",
       "   Prior/Current Therapies :   Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "     1. Treatment with a monoclonal antibody within 4 weeks prior to study Day 1 or has not \n",
       "  recovered (i.e. ,   >=  Grade 1 at baseline) from adverse events due to agents administered \n",
       "   >  4 weeks earlier (intraocular bevacizumab is acceptable).  \n",
       "  2. Prior chemotherapy or targeted small molecule therapy ,  within 3 weeks prior to study \n",
       "  Day 1 or has not reco vered (i.e. ,   >=  Grade 1 at baseline) from adverse events due to a \n",
       "  previously administered agent).  \n",
       "  3. Prior therapy with an anti -PD-1 ,  anti -PD-L1 ,  including durvalumab ,  anti -PDL2 ,  \n",
       "  antiCD137 ,  anti -Cytotoxic T - lymphocyte -associated antigen -4 (CTLA -4) antibody ,  o r \n",
       "  any other antibody or drug specifically targeting T -cell co -stimulation or checkpoint \n",
       "  pathways.  \n",
       "  4. Current or prior use of immunosuppressive medication within 14 days before the first \n",
       "  dose of durvalumab. The following are exceptions to this criterion :   \n",
       "  i. Intranasal ,  inhaled ,  topical steroids ,  or local steroid injections (e.g. ,  intra articular injection) \n",
       "  ii. Systemic corticosteroids at physiologic doses not to exceed  <  < 10 mg/day >  >  of prednisone \n",
       "  or its equivalent iii. Steroids as premedication for hypersensiti vity reactions (e.g. ,  CT scan \n",
       "  premedication) e. Any concurrent chemotherapy ,  IP ,  biologic ,  or hormonal therapy for cancer \n",
       "  treatment. Concurrent use of hormonal therapy for non -cancer -related conditions (e.g. ,  \n",
       "  hormone replacement therapy) is acceptable. f. Prior chemotherapy for this diagnosis of lung \n",
       "  cancer  \n",
       "   Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose \n",
       "  of IP. Note :  Local surgery of isolated lesions for palliative intent is acceptable.  \n",
       "  History of allogenic organ transplantation.  \n",
       "  Severe concurrent illness :   \n",
       "  1. Known psychiatric or substance abuse disorders that would interfere with cooperation \n",
       "  with the requirements of the trial.  \n",
       "  2. Known additional malignancy that is progressing or requires active treatment. \n",
       "  Exceptions include basal cell carcinoma of the skin ,  squamo us cell carcinoma of the \n",
       "  skin ,  or in situ cervical cancer that has undergone potentially curative therapy.  \n",
       "  3. Active infection including tuberculosis (clinical evaluation that includes clinical history ,  \n",
       "  physical examination and radiographic findings ,  and TB t esting in line with local \n",
       "  practice) ,  hepatitis B (known positive HBV surface antigen (HBsAg) result) ,  hepatitis C ,  \n",
       "  or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or \n",
       "  resolved HBV infection (defined as the presence of hep atitis B core antibody [anti -HBc] \n",
       "  and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are \n",
       "  eligible only if polymerase chain reaction is negative for HCV RNA.  Treating Early -stage Non -Small Cell Lung Cancer With Durvalumab and Radiation Therapy - Full Text View - ClinicalTr   09/02/23 ,  19 : 27  \n",
       "     \n",
       "  4. Active infection requiring systemic therapy.  \n",
       "  5. Evidence of intersti tial lung disease or active ,  non -infectious pneumonitis.  \n",
       "  6. Clinically significant (i.e. ,  active) cardiovascular disease :  symptomatic cerebral vascular \n",
       "  accident/stroke ( <  6 months prior to enrollment) ,  myocardial infarction ( <  6 months prior \n",
       "  to enrollment) ,  u nstable angina ,  congestive heart failure (  >=  New York Heart  \n",
       "  Association Classification Class II) ,  or serious cardiac arrhythmia requiring medication.  \n",
       "   Female patients who are pregnant or breastfeeding or male or female patients of reproductive \n",
       "  potential wh o are not willing to employ a highly e ffective birth control from screening to 90 \n",
       "  days after the last dose of durvalumab monotherapy.  \n",
       "  a. Highly e ffective methods of contraception ,  defined as one that results in a low failure rate \n",
       "  (ie ,  less than 1% per year) when used consistently and correctly are described in Appendix B. \n",
       "  Note that some contraception methods are not considered highly e ffective (e.g. male or \n",
       "  female condom with or without spermicide; female cap ,  diaphragm ,  or sponge with or without \n",
       "  spermicide; non -copper containing intrauterine device; progestogen -only oral hormonal \n",
       "  contraceptive pills where inhibition of ovulation is not the primary mo de of action [excluding \n",
       "  Cerazette/desogestrel which is considered highly e ffective]; and triphasic combined oral \n",
       "  contraceptive pills).  \n",
       "   Live vaccination within 4 weeks prior to the first dose of durvalumab and while on trial is \n",
       "  prohibited except for admin istration of inactivated vaccines.  \n",
       "   Connective tissue disorders or idiopathic pulmonary fibrosis involving the lungs and/or \n",
       "  esophagus  \n",
       "  Known actionable EGFR or ALK mutation \n",
       "  Known contraindications to radiotherapy  \n",
       "  History of leptomeningeal carcinomatosis  \n",
       "  History of active primary immunodeficiency  \n",
       "  Known allergy or hypersensitivity to any of the study drugs or any of the study drug \n",
       "  excipients.  \n",
       "   Prior randomization or treatment in a previous durvalumab clinical study regardless of \n",
       "  treatment arm assignment.  \n",
       "   Participants must not donate blood while on durvalumab therapy.}]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "newLis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c4f6c20a",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
